PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2024-01-30

Date Title Company
30-Jan-2024 From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease AccessWire
30-Jan-2024 CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S. AccessWire
30-Jan-2024 Physicians Shift 2024 Tech Investments to Robust Practice Management Platforms With AI, Analytics and Value-Based Care Support Tools, Black Book Survey AccessWire
30-Jan-2024 Cytomos’s Chief Commercial and Innovation Officer Co-Chairs Biannual Conference Advancing Cell and Gene Therapies Cytomos
30-Jan-2024 Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference AccessWire
30-Jan-2024 Pioneer Group and CPI collaborate on ‘Golden Ticket’ programme for planetary health innovations Pioneer Group
30-Jan-2024 Board appointments Cambridge Cognition
30-Jan-2024 Trading Update Cambridge Cognition
30-Jan-2024 MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability AccessWire
30-Jan-2024 MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability MorphoSys AG
30-Jan-2024 Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability MorphoSys AG
30-Jan-2024 MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients AccessWire
30-Jan-2024 Creative Enzymes Revolutionizes the Field with Advanced Industrial Enzyme Production Service Creative Enzymes
30-Jan-2024 Creative Enzymes Introduces Pyranose Oxidase from Microorganism for Enhanced Industrial Applicability Creative Enzymes
30-Jan-2024 BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private Placement AccessWire
30-Jan-2024 CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering AccessWire